Mersana Therapeutics Revenue 2016-2021 | MRSN

Mersana Therapeutics revenue from 2016 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Mersana Therapeutics Annual Revenue
(Millions of US $)
2020 $1
2019 $42
2018 $11
2017 $18
2016 $25
2015 $10
Mersana Therapeutics Quarterly Revenue
(Millions of US $)
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $1
2020-03-31 $0
2019-12-31 $0
2019-09-30 $1
2019-06-30 $0
2019-03-31 $41
2018-12-31 $1
2018-09-30 $2
2018-06-30 $4
2018-03-31 $3
2017-12-31 $3
2017-09-30 $6
2017-06-30 $4
2017-03-31 $4
2016-12-31
2016-09-30 $3
2016-06-30 $6
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.367B $0.001B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81